This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-17 and is reviewed periodically as new material appears.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
== Other related disorders == When sIBM was originally described, the major feature noted was muscle inflammation. Two other disorders were also known to display muscle inflammation, and sIBM was classified along with them. They are dermatomyositis (DM) and polymyositis (PM) and all three illnesses were called idiopathic (of unknown origin) myositis or inflammatory myopathies. It appears that sIBM and polymyositis share some features, especially the initial sequence of immune system activation, however, polymyositis comes on over weeks or months, does not display the subsequent muscle degeneration and protein abnormalities as seen in IBM, and as well, polymyositis tends to respond well to treatments, IBM does not. IBM is often confused with (misdiagnosed as) polymyositis. Polymyositis that does not respond to treatment is likely IBM. Dermatomyositis shares a number of similar physical symptoms and histopathological traits as polymyositis, but exhibits a skin rash not seen in polymyositis or sIBM. It may have different root causes unrelated to either polymyositis or sIBM. Mutations in valosin-containing protein (VCP) cause multisystem proteinopathy (MSP), which can present (among others) as a rare form of inclusion body myopathy.
A money laundering offence under UK legislation need not even involve money, since the money laundering legislation covers assets of any description. In consequence, any person who commits an acquisitive crime (i.e., one that produces some benefit in the form of money or an asset of any description) in the UK inevitably also commits a money laundering offence under UK legislation. This applies also to a person who, by criminal conduct, evades a liability (such as a taxation liability)—which lawyers call "obtaining a pecuniary advantage"—as he is deemed thereby to obtain a sum of money equal in value to the liability evaded. The principal money laundering offences carry a maximum penalty of 14 years' imprisonment. Secondary regulation is provided by the Money Laundering Regulations 2003, which were replaced by the Money Laundering Regulations 2007. They are directly based on the EU Directives 91/308/EEC, 2001/97/EC and (through the 2007 regulations) 2005/60/EC. The regulations list a number of supervisory authorities who have a role in overseeing the financial activities of their members. One consequence of the Act is that solicitors, accountants, tax advisers, and insolvency practitioners who suspect (as a consequence of information received in the course of their work) that their clients (or others) have engaged in tax evasion or other criminal conduct that produced a benefit, now must report their suspicions to the authorities (since these entail suspicions of money laundering).
== Prognosis == There are currently no studies detailing the long term outcome of chronic granulomatous disease with modern treatment. Without treatment, children often die in the first decade of life. The increased severity of X-linked CGD results in a decreased survival rate of patients, as 20% of X-linked patients die of CGD-related causes by the age of 10, whereas 20% of autosomal recessive patients die by the age of 35.Recent experience from centers specializing in the care of patients with CGD suggests that the current mortality has fallen to under 3% and 1% respectively. CGD was initially termed "fatal granulomatous disease of childhood" because patients rarely survived past their first decade in the time before routine use of prophylactic antimicrobial agents. The average patient now survives at least 40 years.
Sources: en.wikipedia.org
=== Initial stranding === The carcass was first spotted on the evening of November 30, 1896, by two young boys, Herbert Coles and Dunham Coretter, while bicycling along Anastasia Island. The enormous mass was half buried in the sand, having sunk under its immense weight. The two boys thought the carcass was the remains of a beached whale, as a similar stranding had occurred two years earlier near the mouth of the Matanzas River, located several miles to the south of St. Augustine (see map). The two boys returned to St. Augustine the same day and reported their discovery to a local physician, Dr. DeWitt Webb. Webb, who was the founder of the St. Augustine Historical Society and Institute of Science, came to the beach the following day, December 1, to examine the remains. He would be the only known person of an academic background to see the specimen in situ. His first impression was that it was the remains of an animal, very mutilated, and in an advanced state of decomposition. The carcass was very pale pink, almost white, in colour, with a silver reflection in the sunlight. It was composed of a rubbery substance of a very hard consistency, such that it could only be cut with great difficulty. The part of the carcass that was visible measured 18 feet (approx. 6 meters) in length and 7 feet (approx. 2+1⁄2 meters) in width. Webb estimated its weight at nearly 5 tons, if not more. He believed it was the remains of a giant octopus, as it appeared to have the stumps of four arms, with another arm buried nearby.
2-Bromodeschloroketamine (also known as 2-Br-2'-Oxo-PCM and bromoketamine) is a chemical compound of the arylcyclohexylamine class, which is an analog of the dissociative anesthetic drug ketamine in which the chlorine atom has been replaced with a bromine atom. Its specific pharmacological activities have not been studied. It is used in scientific research as a comparison or control compound in studies into the metabolism of ketamine and norketamine. It has been sold online as a designer drug.
Carbon dioxide is colorless. At low concentrations, the gas is odorless; however, at sufficiently high concentrations, it has a sharp, acidic odor. At standard temperature and pressure, the density of carbon dioxide is around 1.98 kg/m3, about 1.53 times that of air. Carbon dioxide has no liquid state at pressures below 0.51795(10) MPa (5.11177(99) atm). At a pressure of 1 atm (0.101325 MPa), the gas deposits directly to a solid at temperatures below 194.6855(30) K (−78.4645(30) °C) and the solid sublimes directly to a gas above this temperature. In its solid state, carbon dioxide is commonly called dry ice.
=== Without insulin === When carbohydrate counting is used without insulin, it can be used as a tool to manage blood sugar levels. A certain number of carbohydrate grams or carbohydrate units is consumed with each meal and with each snack. In keeping the carbohydrate at a certain level, the blood sugar is able to remain within a normal level. The American Diabetes Association recommends starting at around 45–60 carbohydrate grams (3–4 carb units) at each meal, with potential to increase or decrease that amount.
Sources: en.wikipedia.org
==== Metabolism ==== Minoxidil is a prodrug of minoxidil sulfate, which can be formed both systemically and locally within hair follicles. This active metabolite is 14-fold more potent than minoxidil in stimulating cysteine incorporation in cultured rodent hair follicles ex vivo. Similarly to minoxidil, it also stimulates hair follicle growth. Minoxidil is sulfated into minoxidil sulfate by at least four cytosolic sulfotransferase enzymes found in skin, scalp, smooth muscle, liver, and fibroblasts. The primary sulfotransferase involved in sulfation of minoxidil in hair follicles is SULT1A1, whereas in the liver, it is SULT2A1. Expression of this enzyme has been found to predict the effectiveness of topical minoxidil. Oral minoxidil is subject to first-pass metabolism, including rapid and extensive metabolism in the liver. A majority of orally administered minoxidil, about 90%, is metabolized in the liver via glucuronidation, hydroxylation, and sulfation, with glucuronidation being the primary metabolic pathway and minoxidil glucuronide being the predominant metabolite of minoxidil. Conversely, topical minoxidil bypasses the first pass through the liver and is not subject to first-pass metabolism. Similarly, sublingual minoxidil also bypasses first-pass metabolism.
The two substrates of this enzyme are sn-glycerol 3-phosphate and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are dihydroxyacetone phosphate, the reduced cofactor NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sn-glycerol-3-phosphate:NAD+ 2-oxidoreductase. Other names in common use include alpha-glycerol phosphate dehydrogenase (NAD+), alpha-glycerophosphate dehydrogenase (NAD+), glycerol 1-phosphate dehydrogenase, glycerol phosphate dehydrogenase (NAD+), glycerophosphate dehydrogenase (NAD+), hydroglycerophosphate dehydrogenase, L-alpha-glycerol phosphate dehydrogenase, L-alpha-glycerophosphate dehydrogenase, L-glycerol phosphate dehydrogenase, L-glycerophosphate dehydrogenase, NAD+-alpha-glycerophosphate dehydrogenase, NAD+-dependent glycerol phosphate dehydrogenase, NAD+-dependent glycerol-3-phosphate dehydrogenase, NAD+-L-glycerol-3-phosphate dehydrogenase, NAD+-linked glycerol 3-phosphate dehydrogenase, NADH-dihydroxyacetone phosphate reductase, and glycerol-3-phosphate dehydrogenase (NAD+). This enzyme participates in glycerophospholipid metabolism.
Other uses for genetically modified bacteria include bioremediation, where the bacteria are used to convert pollutants into a less toxic form. Genetic engineering can increase the levels of the enzymes used to degrade a toxin or to make the bacteria more stable under environmental conditions. Bioart has also been created using genetically modified bacteria. In the 1980s artist Jon Davis and geneticist Dana Boyd converted the Germanic symbol for femininity (ᛉ) into binary code and then into a DNA sequence, which was then expressed in Escherichia coli. This was taken a step further in 2012, when a whole book was encoded onto DNA. Paintings have also been produced using bacteria transformed with fluorescent proteins.
=== Navarro et al. method === For particles larger than 30 nm, control of particle size with a low polydispersity of spherical gold nanoparticles remains challenging. In order to provide maximum control on the NP structure, Navarro and co-workers used a modified Turkevitch-Frens procedure using sodium acetylacetonate as the reducing agent and sodium citrate as the stabilizer.
Opportunistic bands of Normans successfully established a foothold in southern Italy. Probably as the result of returning pilgrims' stories, the Normans entered southern Italy as warriors in 1017 at the latest. In 999, according to Amatus of Montecassino, Norman pilgrims returning from Jerusalem called in at the port of Salerno when a Muslim attack occurred. The Normans fought so valiantly that Prince Guaimar III begged them to stay, but they refused and instead offered to tell others back home of the Prince's request. William of Apulia tells that, in 1016, Norman pilgrims to the shrine of the Archangel Michael at Monte Gargano were met by Melus of Bari, a Lombard nobleman and rebel, who persuaded them to return with more warriors to help throw off the Byzantine rule, which they did. The two most prominent Norman families to arrive in the Mediterranean were descendants of Tancred of Hauteville and the Drengot family. A group of Normans with at least five brothers from the Drengot family fought the Byzantines in Apulia under the command of Melus of Bari. Between 1016 and 1024, in a fragmented political context, the County of Ariano was founded by another group of Norman knights headed by Gilbert Buatère and hired by Melus of Bari. Defeated at Cannae, Melus of Bari escaped to Bamberg, Germany, where he died in 1022. The county, which replaced the pre-existing chamberlainship, is considered to be the first political body established by the Normans in the south of Italy.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.